226 related articles for article (PubMed ID: 32907617)
1. Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials.
Genovese MC; Burmester GR; Hagino O; Thangavelu K; Iglesias-Rodriguez M; John GS; González-Gay MA; Mandrup-Poulsen T; Fleischmann R
Arthritis Res Ther; 2020 Sep; 22(1):206. PubMed ID: 32907617
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
Genovese MC; Fleischmann R; Kivitz A; Lee EB; van Hoogstraten H; Kimura T; St John G; Mangan EK; Burmester GR
Arthritis Res Ther; 2020 Jun; 22(1):139. PubMed ID: 32522251
[TBL] [Abstract][Full Text] [Related]
3. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.
Rubbert-Roth A; Furst DE; Fiore S; Praestgaard A; Bykerk V; Bingham CO; Charles-Schoeman C; Burmester G
Arthritis Res Ther; 2022 Aug; 24(1):207. PubMed ID: 36008838
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
[TBL] [Abstract][Full Text] [Related]
5. Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis.
Boyapati A; Schwartzman S; Msihid J; Choy E; Genovese MC; Burmester GR; Lam G; Kimura T; Sadeh J; Weinreich DM; Yancopoulos GD; Graham NMH
Arthritis Rheumatol; 2020 Sep; 72(9):1456-1466. PubMed ID: 32343882
[TBL] [Abstract][Full Text] [Related]
6. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.
Huizinga TW; Fleischmann RM; Jasson M; Radin AR; van Adelsberg J; Fiore S; Huang X; Yancopoulos GD; Stahl N; Genovese MC
Ann Rheum Dis; 2014 Sep; 73(9):1626-34. PubMed ID: 24297381
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
Burmester GR; Lin Y; Patel R; van Adelsberg J; Mangan EK; Graham NM; van Hoogstraten H; Bauer D; Ignacio Vargas J; Lee EB
Ann Rheum Dis; 2017 May; 76(5):840-847. PubMed ID: 27856432
[TBL] [Abstract][Full Text] [Related]
8. High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab.
Strand V; Boklage SH; Kimura T; Joly F; Boyapati A; Msihid J
Arthritis Res Ther; 2020 Oct; 22(1):250. PubMed ID: 33081825
[TBL] [Abstract][Full Text] [Related]
9. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
Gossec L; Strand V; Proudfoot C; Chen CI; Guillonneau S; Kimura T; van Hoogstraten H; Mangan E; Reaney M
J Rheumatol; 2019 Oct; 46(10):1259-1267. PubMed ID: 30877216
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
Genovese MC; van der Heijde D; Lin Y; St John G; Wang S; van Hoogstraten H; Gómez-Reino JJ; Kivitz A; Maldonado-Cocco JA; Seriolo B; Stanislav M; Burmester GR
RMD Open; 2019; 5(2):e000887. PubMed ID: 31452928
[TBL] [Abstract][Full Text] [Related]
11. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
Gabay C; Burmester GR; Strand V; Msihid J; Zilberstein M; Kimura T; van Hoogstraten H; Boklage SH; Sadeh J; Graham NMH; Boyapati A
Arthritis Res Ther; 2020 Apr; 22(1):70. PubMed ID: 32264972
[TBL] [Abstract][Full Text] [Related]
12. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
Strand V; Kosinski M; Chen CI; Joseph G; Rendas-Baum R; Graham NM; van Hoogstraten H; Bayliss M; Fan C; Huizinga T; Genovese MC
Arthritis Res Ther; 2016 Sep; 18(1):198. PubMed ID: 27600829
[TBL] [Abstract][Full Text] [Related]
13. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
Tanaka Y; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham NMH; Kameda H
Arthritis Res Ther; 2019 Mar; 21(1):79. PubMed ID: 30894208
[TBL] [Abstract][Full Text] [Related]
14. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.
Boyapati A; Msihid J; Fiore S; van Adelsberg J; Graham NM; Hamilton JD
Arthritis Res Ther; 2016 Oct; 18(1):225. PubMed ID: 27716324
[TBL] [Abstract][Full Text] [Related]
15. Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA).
Kameda H; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham N; Tanaka Y
Mod Rheumatol; 2020 Mar; 30(2):239-248. PubMed ID: 31268376
[No Abstract] [Full Text] [Related]
16. Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab.
Choy E; Bykerk V; Lee YC; van Hoogstraten H; Ford K; Praestgaard A; Perrot S; Pope J; Sebba A
Rheumatology (Oxford); 2023 Jul; 62(7):2386-2393. PubMed ID: 36413080
[TBL] [Abstract][Full Text] [Related]
17. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis.
Lamb YN; Deeks ED
Drugs; 2018 Jun; 78(9):929-940. PubMed ID: 29931592
[TBL] [Abstract][Full Text] [Related]
18. Haemoglobin changes and disease activity in Japanese patients with rheumatoid arthritis treated with sarilumab.
Tanaka Y; Takahashi T; Van Hoogstraten H; Praestgaard A; Kato N; Kameda H
Clin Exp Rheumatol; 2023 May; 41(5):1129-1139. PubMed ID: 36305354
[TBL] [Abstract][Full Text] [Related]
19. Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis.
Boyce EG; Rogan EL; Vyas D; Prasad N; Mai Y
Ann Pharmacother; 2018 Aug; 52(8):780-791. PubMed ID: 29482351
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis.
Burmester GR; Strand V; Kivitz AJ; Hu CC; Wang S; van Hoogstraten H; Klier GL; Fleischmann R
Rheumatology (Oxford); 2023 Oct; 62(10):3268-3279. PubMed ID: 36727470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
